Skip to main content

Table 5 Fecal immunochemical test distribution in the validation set

From: Improvement of Asia-Pacific colorectal screening score and evaluation of its use combined with fecal immunochemical test

 

AR (0–2)

HR (≥3)

Se-1a (%)

Se-2a (%)

Se-3a (%)

NPV −1b (%)

NPV −2b (%)

NPV −3b (%)

n (%)

FIT-

FIT+

n (%)

FIT-

FIT+

ACN

9 (2.2)

7

2

21 (6.4)

12

9

76.7%

36.7%

70.0%

98.0%

97.0%

97.9%

Advanced adenoma

9 (2.2)

7

2

16 (4.9)

11

5

72.0%

28.0%

64.0%

98.0%

97.2%

97.9%

CRC

0 (0)

0

0

5 (1.5)

1

4

100.0%

80.0%

100.0%

100.0%

99.8%

100.0%

Nonadvanced neoplasia

64 (15.4)

52

12

110 (33.6)

97

13

70.1%

14.4%

63.2%

85.4%

76.9%

84.9%

Negative

342 (82.4)

291

51

196 (59.9)

166

30

      

Total

415 (100)

350

65

327 (100)

275

52

      
  1. ACN Advanced colorectal neoplasia, CRC Colorectal cancer, AR Average risk, HR High risk, FIT Fecal immunochemical test, NPV Negative predictive value
  2. aSe-1~3: sensitivity of the modified APCS score combined with fecal immunochemical test (Se-1), of fecal immunochemical test alone (Se-2), and of the modified APCS score alone (Se-3) for screening high risk cohorts for colonoscopy
  3. bNPV-1~3: NPV of the modified APCS score combined with fecal immunochemical test (NPV-1), of fecal immunochemical test alone (NPV-2), and of the modified APCS score alone (NPV-3) for screening high risk cohorts for colonoscopy